Paul W G Wijnhoven
Overview
Explore the profile of Paul W G Wijnhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, et al.
Nat Med
. 2024 Feb;
30(5):1506.
PMID: 38332041
No abstract available.
2.
Sharma A, Ramlee M, Kosmin J, Higgs M, Wolstenholme A, Ronson G, et al.
Nat Commun
. 2023 Nov;
14(1):7784.
PMID: 38012134
No abstract available.
3.
Sharma A, Ramlee M, Kosmin J, Higgs M, Wolstenholme A, Ronson G, et al.
Nat Commun
. 2023 Aug;
14(1):5003.
PMID: 37591890
While the toxicity of PARP inhibitors to cells with defects in homologous recombination (HR) is well established, other synthetic lethal interactions with PARP1/PARP2 disruption are poorly defined. To inform on...
4.
Serra V, Wang A, Castroviejo-Bermejo M, Polanska U, Palafox M, Herencia-Ropero A, et al.
Clin Cancer Res
. 2022 Aug;
28(20):4536-4550.
PMID: 35921524
Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most...
5.
Wilson Z, Odedra R, Wallez Y, Wijnhoven P, Hughes A, Gerrard J, et al.
Cancer Res
. 2022 Jan;
82(6):1140-1152.
PMID: 35078817
Significance: This detailed preclinical investigation, including pharmacokinetics/pharmacodynamics and dose-schedule optimizations, of AZD6738/ceralasertib alone and in combination with chemotherapy or PARP inhibitors can inform ongoing clinical efforts to treat cancer with...
6.
Gill S, Wijnhoven P, Fok J, Lloyd R, Cairns J, Armenia J, et al.
Mol Cancer Ther
. 2021 Jun;
20(9):1614-1626.
PMID: 34158341
Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here, we assess the radiopotentiation profiles of DNA damage response...
7.
Lloyd R, Wijnhoven P, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, et al.
Oncogene
. 2020 May;
39(25):4869-4883.
PMID: 32444694
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA...
8.
Fok J, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven P, Follia V, James N, et al.
Nat Commun
. 2019 Nov;
10(1):5065.
PMID: 31699977
DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR) and instrumental in the non-homologous end-joining pathway (NHEJ) used to detect and repair DNA double-strand breaks...
9.
Nishi R, Wijnhoven P, Kimura Y, Matsui M, Konietzny R, Wu Q, et al.
Sci Rep
. 2018 Dec;
8(1):17891.
PMID: 30559450
Non-homologous end-joining (NHEJ), which can promote genomic instability when dysfunctional, is a major DNA double-strand break (DSB) repair pathway. Although ubiquitylation of the core NHEJ factor, Ku (Ku70-Ku80), which senses...
10.
Balmus G, Barros A, Wijnhoven P, Lescale C, Hasse H, Boroviak K, et al.
Genes Dev
. 2016 Nov;
30(19):2152-2157.
PMID: 27798842
PAXX was identified recently as a novel nonhomologous end-joining DNA repair factor in human cells. To characterize its physiological roles, we generated Paxx-deficient mice. Like Xlf mice, Paxx mice are...